Search

Your search keyword '"Fröhlich, Hanna"' showing total 127 results
Start Over Author "Fröhlich, Hanna"
127 results on '"Fröhlich, Hanna"'

11. Glycaemic control and insulin therapy are significant confounders of the obesity paradox in patients with heart failure and diabetes mellitus

Author

Fröhlich, Hanna, primary, Bossmeyer, Anna, additional, Kazmi, Syed, additional, Goode, Kevin M., additional, Agewall, Stefan, additional, Atar, Dan, additional, Grundtvig, Morten, additional, Frey, Norbert, additional, Cleland, John G. F., additional, Frankenstein, Lutz, additional, Clark, Andrew L., additional, and Täger, Tobias, additional

Published
2023
Full Text
View/download PDF

15. Long-Term Trajectories of Biomarkers, Functional, and Echocardiographic Parameters in Patients with Chronic Heart Failure from Dilated or Ischaemic Cardiomyopathy.

Author

Täger, Tobias, Rößmann, Paulina, Frey, Norbert, Estler, Bent, Mäck, Mirjam, Schlegel, Philipp, Beckendorf, Jan, Frankenstein, Lutz, and Fröhlich, Hanna

Subjects
HEART failure patients, DILATED cardiomyopathy, ECHOCARDIOGRAPHY, VENTRICULAR ejection fraction, HEART failure
Abstract

Introduction: The long-term evolution of clinical, echocardiographic, and laboratory parameters of cardiac function in patients with chronic heart failure (HF) with either reduced (HFrEF) or mildly reduced (HFmrEF) left ventricular ejection fraction (LVEF) is incompletely characterised. Methods: We identified patients with chronic stable HF who presented at least twice to a university HF outpatient clinic between 1995 and 2021. Trajectories of NYHA functional class, LVEF, left ventricular internal end-diastolic diameter (LVIDD), NT-proBNP concentrations, and HF treatment over 10 years of follow-up were analysed using fractional polynomials. Analyses were repeated after stratifying patients according to aetiology (ischaemic vs. dilated) or HF category (HFrEF vs. HFmrEF). Results: A total of 2,132 patients were included, of whom 51% had ischaemic and 49% had dilated HF. Eighty six percent and 14% were classified as HFrEF and HFmrEF, respectively. Mean LVEF was 28 ± 10%, and median NT-proBNP and estimated glomerular filtration rate values were 1,170 (385–3,176) pmol/L and 81 (62–100) mL/min/1.73 m2, respectively. Median follow-up was 5.2 (2.6–9.2) years. Overall, NYHA functional class and LVIDD trajectories were U-shaped, whereas LVEF and NT-proBNP concentrations markedly improved during the first year and remained stable thereafter. However, the evolution of HF parameters significantly differed with respect to HF category and aetiology, with greater improvements seen in patients with HFrEF of non-ischaemic origin. Improvements in HF variables were associated with optimization of HF therapy, notably with initiation and up-titration of renin-angiotensin-system blockers. Conclusion: This study provides insights into the natural history of HF in a large cohort of well-treated chronic HF outpatients with respect to subgroups of HF and different aetiologists. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Prognostic value of changes in high-sensitivity cardiac troponin T beyond biological variation in stable outpatients with cardiovascular disease: a validation study

Author

Biener, Moritz, primary, Giannitsis, Evangelos, additional, Hogrefe, Katharina, additional, Mueller-Hennessen, Matthias, additional, Fröhlich, Hanna, additional, Katus, Hugo A., additional, Frey, Norbert, additional, Frankenstein, Lutz, additional, and Täger, Tobias, additional

Published
2021
Full Text
View/download PDF

24. Impact of the introduction of percutaneous edge-to-edge mitral valve reconstruction on clinical practice in Germany compared to surgical valve repair

Author

Frankenstein, Lutz, primary, Kaier, Klaus, additional, Katus, Hugo A., additional, Bode, Christoph, additional, Wengenmayer, Tobias, additional, von zur Mühlen, Constantin, additional, Bekeredjian, Raffi, additional, Täger, Tobias, additional, Zehender, Manfred, additional, Fröhlich, Hanna, additional, and Stachon, Peter, additional

Published
2020
Full Text
View/download PDF

25. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

Author

Täger, Tobias, primary, Atar, Dan, additional, Agewall, Stefan, additional, Katus, Hugo A., additional, Grundtvig, Morten, additional, Cleland, John G. F., additional, Clark, Andrew L., additional, Fröhlich, Hanna, additional, and Frankenstein, Lutz, additional

Published
2020
Full Text
View/download PDF

26. Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study

Author

Fröhlich, Hanna, Henning, Felix, Täger, Tobias, Schellberg, Dieter, Grundtvig, Morten, Goode, Kevin, Corletto, Anna, Kazmi, Syed, Hole, Torstein, Katus, Hugo A., Atar, Dan, Cleland, John G.F., Agewall, Stefan, Frankenstein, Lutz, and Clark, Andrew L.

Subjects
cardiovascular diseases, R1, circulatory and respiratory physiology
Abstract

Background: Angiotensin converting enzyme inhibitors (ACEIs) are recommended as first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of different ACEIs is not known.\ud Methods and results: 4,723 out-patients with stable HFrEF prescribed either enalapril, lisinopril, or ramipril were identified from three registries in Norway, England, and Germany. In three separate matching procedures, patients were individually matched with respect to both dose equivalents and their respective propensity scores for ACEI treatment.\ud During a follow-up of 21,939 patient-years, 360 (49.5%), 337 (52.4%), and 1,119 (33.4%) patients died amongst those prescribed enalapril, lisinopril, and ramipril, respectively. In univariable analysis of the general sample, enalapril and lisinopril were both associated with higher mortality as compared with ramipril treatment (HR 1.46, 95% CI 1.30-1.65, p

Published
2018

27. Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure – A multicenter propensity score matched analysis

Author

Täger, Tobias, primary, Fröhlich, Hanna, additional, Grundtvig, Morten, additional, Seiz, Mirjam, additional, Schellberg, Dieter, additional, Goode, Kevin, additional, Kazmi, Syed, additional, Hole, Torstein, additional, Katus, Hugo A., additional, Atar, Dan, additional, Cleland, John G.F., additional, Agewall, Stefan, additional, Clark, Andrew L., additional, and Frankenstein, Lutz, additional

Published
2019
Full Text
View/download PDF

28. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials

Author

Frankenstein, Lutz, primary, Seide, Svenja, additional, Täger, Tobias, additional, Jensen, Katrin, additional, Fröhlich, Hanna, additional, Clark, Andrew L., additional, Seiz, Mirjam, additional, Katus, Hugo A., additional, Nee, Paul, additional, Uhlmann, Lorenz, additional, Naci, Huseyin, additional, and Atar, Dan, additional

Published
2019
Full Text
View/download PDF

30. Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe

Author

Fröhlich, Hanna, primary, Rosenfeld, Niklas, additional, Täger, Tobias, additional, Goode, Kevin, additional, Kazmi, Syed, additional, Hole, Torstein, additional, Katus, Hugo A, additional, Atar, Dan, additional, Cleland, John G F, additional, Agewall, Stefan, additional, Clark, Andrew L, additional, Frankenstein, Lutz, additional, and Grundtvig, Morten, additional

Published
2019
Full Text
View/download PDF

31. Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study

Author

Fröhlich, Hanna, primary, Henning, Felix, additional, Täger, Tobias, additional, Schellberg, Dieter, additional, Grundtvig, Morten, additional, Goode, Kevin, additional, Corletto, Anna, additional, Kazmi, Syed, additional, Hole, Torstein, additional, Katus, Hugo A, additional, Atar, Dan, additional, Cleland, John G F, additional, Agewall, Stefan, additional, Frankenstein, Lutz, additional, and Clark, Andrew L, additional

Published
2017
Full Text
View/download PDF

32. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease

Author

Fröhlich, Hanna, primary, Nelges, Christoph, additional, Täger, Tobias, additional, Schwenger, Vedat, additional, Cebola, Rita, additional, Schnorbach, Johannes, additional, Goode, Kevin M., additional, Kazmi, Syed, additional, Katus, Hugo A., additional, Cleland, John G.F., additional, Clark, Andrew L., additional, and Frankenstein, Lutz, additional

Published
2016
Full Text
View/download PDF

33. Periodontitis in Chronic Heart Failure

Author

Fröhlich, Hanna, primary, Herrmann, Kristina, primary, Franke, Jennifer, primary, Karimi, Alamara, primary, Täger, Tobias, primary, Cebola, Rita, primary, Katus, Hugo A., primary, Zugck, Christian, primary, and Frankenstein, Lutz, primary

Published
2016
Full Text
View/download PDF

36. Biological variation of the cardiac index in patients with stable chronic heart failure: inert gas rebreathing compared with impedance cardiography

Author

Täger, Tobias, primary, Fröhlich, Hanna, additional, Franke, Jennifer, additional, Slottje, Karen, additional, Horsch, Andrea, additional, Zdunek, Dietmar, additional, Hess, Georg, additional, Dösch, Andreas, additional, Katus, Hugo A., additional, Wians, Frank H., additional, and Frankenstein, Lutz, additional

Published
2015
Full Text
View/download PDF

37. Peritoneal ultrafiltration in end-stage chronic heart failure.

Author

Fröhlich, Hanna, Katus, Hugo A., Täger, Tobias, Lossnitzer, Nicole, Grossekettler, Leonie, Kihm, Lars, Zeier, Martin, Remppis, Andrew, Frankenstein, Lutz, and Schwenger, Vedat

Subjects
*ULTRAFILTRATION, *HEART failure treatment, *QUALITY of life, *HOSPITAL care, *HEMODIALYSIS
Abstract

Background. Cardiorenal syndrome type 2 (CRS-2) is common in end-stage chronic heart failure (CHF). Peritoneal ultrafiltration (pUF) may entail clinical functional improvement and a reduction in hospitalizations. Methods. Thirty-nine consecutive end-stage CHF patients with stable CRS-2 were initiated on ambulatory pUF after interdisciplinary cardiological/nephrological evaluation and prospectively followed for 1 year. All-cause hospitalization was the primary end point. Secondary end points included mortality, treatment alteration and change in weight, NYHA functional class or quality of life (QoL). Outcomes were compared both within the pUF cohort (365 prior to initiation) and with 39 matched CHF patients receiving standard medical treatment. Results. Compared with pretreatment, there was a trend to a reduction in 1-year hospitalization days in the pUF group (P = 0.07). One-year mortality was 33% in the pUF group and 23% in the matched control cohort. pUF was stopped in eight patients (18%) due to recurrent peritonitis (n = 3), insufficient ultrafiltration (n = 3) or cardiac recompensation (n = 1). Compared with standard medical treatment, pUF significantly improved volume overload (P < 0.05), NYHA functional class (P < 0.001) and mental health (P < 0.05). Moreover, hospitalization days for all causes as well as cardiovascular hospitalization days were significantly reduced during the interim periods in the pUF group (P < 0.05 and P < 0.001, respectively). Conclusions. pUF is effective in improving the clinical condition of end-stage CHF patients suffering from CRS-2. Randomized controlled trials are needed to clarify the effects of pUF on hospitalization and mortality in these patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results